Khaitan & Co has advised Merck Sharp & Dohme B.V. (MSD BV) and Organon India Private Ltd (OPIL) in relation to acquisition by Piramal Enterprises Ltd (PEL) of five trademark rights from OPIL and MSD B.V for $13.8m approximately.
The acquisition includes mainly the brands Naturolax, Lactobacil and Farizym, which PEL intends to continue in the Gastro-Intestinal segment through the over-the –counter route. MSD BV and OIPL currently operates in various therapeutic areas in human health, including metabolics, cardiovascular, vaccines, critical care, immunology, virology, oncology, women’s health, dermatology, respiratory, musculoskeletal and primary care, and offers a strong and diversified product portfolio of over 60 brands in total.
The core transaction team included Bhavik Narsana, partner; Shweta Dwivedi, senior associate and Abhinav Bhatia, associate advising on the corporate aspects with assistance from Adheesh Nargolkar, partner; Shailendra Bhandare, principal associate and Alisha Ganjawala, associate on the intellectual property aspects and Avaantika Kakkar, partner and Anshuman Sakle, senior associate on the competition law aspects.